Good morning, everyone. My name is Hidetaka Shirozume, President and Chief Executive Officer at the Adeka Corporation. Thank you for taking the time out of your busy schedules to participate in today's briefing. Allow me to start today's briefing on financial results for the Adeka Corporation for the Q1 of fiscal year 2025. Today's briefing will cover the following agenda items. First are the consolidated results for the Q1 of fiscal year 2025. We registered JPY 101.6 billion in net sales, up JPY 3.4 billion on a YOY basis. JPY 10.9 billion in operating profit, up JPY 2.3 billion. JPY 11 billion in ordinary profit, up JPY 1.3 billion. 7.2 Billion yen in profit attributable to owners of parent, up JPY 400 million. Lastly, we registered JPY 71.2 in net profit per share, up 4.4 JPY per share. Next is an analysis of operating profit. While an increase in fixed costs and an unfavorable foreign exchange market environment represented headwinds for operating profit, this was offset by higher sales volume and benefits from net pricing. Ultimately, these factors translated into YOY operating profit growth. Next are the trends in consolidated performance by segment. On a year-over-year basis, while we faced a challenging environment in the chemicals and food products segments, this was more than offset by a significant lift in both net sales and operating profit in the life science segment. I would now like to give you a more in-depth review of the results for each segment, starting with polymer additives in the chemicals segment. We recorded a slight YOY decline in net sales. A slump in the home appliances market led to weak sales of flame retardants. Additionally, weak demand in China and the U.S. for engineering plastics for automotive materials and other applications translated into weak sales of antioxidants. Sales were also weak for plasticizers used in food packaging materials, but steady for PVC stabilizers for home interior materials. We recorded a steep decline in operating profit on a YOY basis due to adverse net pricing, lower sales volume, and an unfavorable exchange rate. Next are the results for semiconductor materials in the chemicals segment. Net sales and operating profit both experienced a steep decline. We saw weak sales of high-K materials, particularly legacy products. This was due to production adjustments in the market associated with the generational change in DRAM. Conversely, sales of semiconductor lithography materials for advanced photoresists were strong, driven by the expansion of investment in data centers and devices equipped with generative AI. Operating profit was impacted by a slew of negative factors, namely adverse net pricing, higher fixed costs, and an unfavorable exchange rate. Next are the results for environmental materials in the chemicals segment. Net sales recorded a slight decline while operating profit saw a slight increase. Here are the main factor highlights for sales on a YOY basis. Starting with the domain of mobility, sales were strong for lubricant additives for engine oil, catering to fuel efficiency needs in Asia and the U.S. Conversely, sales were weak for photo curing materials for use in electronics due to production adjustments of large panels in the market. We registered steady sales of raw ingredients such as glycol for use in cosmetics, while sales for reactive emulsifiers for architectural and infrastructure uses were weak. An increase in sales volume lifted operating profit, but these gains were offset by an increase in fixed costs and an unfavorable exchange rate. All in all, operating profit delivered a modest YOY increase of 0.6%. Next is the food products segment. Net sales decreased slightly on a YOY basis while operating profit was down significantly. Here are the main factor highlights for sales. Sales of shortening and margarines for use in breads and confectioneries were weak as customers in China remained oriented to low prices due to the economic downturn in the country. Conversely, within the category of cafe and breads, we saw steady sales of our Deli-PLANTS series of plant-based foods, thanks to growing adoption on cafe menus in Japan. Additionally, we sold Uehara Foods Industry Co., Ltd., a consolidated subsidiary, effective on April 1, 2025. A decrease in sales volume significantly weighed on operating profit, while improvements from net pricing had a positive impact. Next is the life science segment, which delivered a significant YOY increase in both net sales and operating profit. Here are the main factor highlights for sales. Starting with agrochemicals, soaring rice prices in Japan have led to an increase in rice acreage. This, in turn, translated into strong sales of herbicides and insecticides. In North America, US tariffs went into effect, boosting the movement of goods to distributors. Sales were strong for herbicides used during wheat and rapeseed cultivation and for fungicides used to protect fruit. In Europe, sales were strong for active ingredients of insecticides as well as sales of herbicides used in fruit and potato cultivation. An increase in sales volume and net pricing drove a significant increase in operating profit, more than offsetting the negative impact from higher fixed costs and an unfavorable exchange rate. Next are the consolidated forecasts for fiscal year 2025. The forecasts remain unchanged from the targets announced in May 2025. We are guiding for JPY 441 billion in net sales on a full fiscal year basis, JPY 43 billion in operating and ordinary profit, JPY 26.4 billion in profit attributable to owners of parent, and JPY 259.5 in net profit per share. To reiterate, the targets remain the same. Next are the consolidated forecasts by segment. Although we are expecting a significant recovery in the second half of fiscal year 2025, we don't think second half results will be enough to offset the YOY decrease we recorded in the first half in the semiconductor materials business. The two waterfall charts show a breakdown of the changes from the previous forecasts for each segment. Higher expected net sales from the Life Science segment are sufficient to offset lower guidance for polymer additives and semiconductor materials. As a result, the net sales forecast for fiscal year 2025 remains unchanged. The same dynamic holds true for operating profit, with higher expected results in the Life Science segment offsetting slightly lower guidance for polymer additives and semiconductor materials. In summary, the net sales and operating profit results forecasts remain unchanged. I would now like to go over the more relevant changes from the previous forecasts, starting with polymer additives in the Chemicals segment. While we have raised the net sales forecast for the second half, we believe it's somewhat unlikely we will be able to fully offset the shortfall from the first half. The same dynamic applies to the revised operating profit forecasts. In the second half, we will be focusing most intensively on global sales expansion of the new clarifier, through which we expect to be able to unlock net sales and operating profit growth. Next are the relevant changes from the previous forecasts for the semiconductor materials in the Chemicals segment. The overall trend is similar to the one observed in the polymer additives business. Therefore, our strategy for the second half is to make a number of efforts to try to make up for the shortfall from the first half in terms of both net sales and operating profit, though we recognize this will be a significant challenge. While we continue making good progress in the stepwise launch of new products, we are also expecting an increase in fixed costs, so the rest of fiscal year 2025 will be a bit of a balancing act. Next is the Life Science segment. We have revised the net sales and operating profit forecasts, taking a strong first-half results performance and using that to build a buffer in the second half and drive good full fiscal year results. Companies front-loaded shipments of agrochemicals and ingredients ahead of the implementation of U.S. tariffs and the reciprocal tariff regime. As this temporary demand will be absent in the second half, we expect lower sales as well as an increase in fixed costs. Taking all of this into account, we expect a slight YOY increase in the metrics of net sales and operating profit. I would now like to discuss a key topic. As announced on August 8, 2025, the Adeka Corporation has decided on the acquisition and cancellation of its own shares. The purpose of this share buyback operation is to increase shareholder returns and raise the level of the share price. This share repurchase operation has an upper limit of JPY 18 billion of the company's own funds and will run from August 12, 2025 to May 31, 2026. Lastly, the scheduled date of cancellation has been set for around early June, 2026. Next, we have some supplementary data for your reference. As of the end of the Q1 of fiscal year 2025, the overseas sales ratio stood at just under 55%. Next are the business goals and a review of first year performance. The next fiscal year marks the final year of ADX 2026. We are guiding for an operating profit of JPY 53 billion on net sales of JPY 500 billion. We are also committed to our targets of 11% for ROE and 10.5% for ROIC. The other targets also remain unchanged, and we will do our utmost to persevere and deliver satisfactory results in fiscal year 2025. Last is the trend in consolidated performance. It's still early in the year, but as of the end of the Q1, the progress rate stood at 23% for net sales and 25% for operating profit. This concludes today's briefing. Thank you for your time.